Use_of_recombinant_human_interleukin-2_in_conjunction_with_syngeneic_bone_marrow_transplantation_in_mice_as_a_model_for_control_of_minimal_residual_disease_in_malignant_hematologic_disorders._Unlike_allogeneic_bone_marrow_transplantation_(BMT),_autologous_BMT_is_not_accompanied_by_immune-mediated_graft-versus-leukemia_(GVL)_effects;_hence,_the_relapse_rate_observed_after_autologous_BMT_in_malignant_hematologic_disorders_is_higher_than_that_observed_after_allogeneic_BMT._Autologous_BMT_represents_a_much_safer_medical_procedure_available_for_many_patients_in_need_in_situations_where_allogeneic_BMT_is_not_feasible_or_risky._The_present_experiments_were_designed_to_investigate_whether_it_might_be_possible_to_combine_the_therapeutic_benefits_of_autologous_BMT_with_additional_immunotherapy_after_BMT._The_tumor_model_used_for_investigating_GVL_effects_was_the_murine_B-cell_leukemia_(BCL1),_a_spontaneous,_nonimmunogenic,_highly_lethal_leukemia_of_BALB/c_origin._BALB/c_mice_inoculated_with_10(3)_BCL1_leukemia_cells_were_treated_on_day-1_with_cyclophosphamide_100_mg/kg_and_transplanted_with_normal_syngeneic_BM_cells_on_day_0._High-dose_recombinant_interleukin-2_(rIL-2)_(100,000_Cetus_units_x_3/day_intraperitoneally_x_5_consecutive_days)_was_initiated_on_day_+1,_+7,_or_+21_after_BMT._Kinetics_of_lymphocyte_reconstitution_after_syngeneic_BMT_indicated_a_steep_increase_in_the_absolute_number_of_peripheral_blood_lymphocytes_on_days_17_through_24._All_experimental_groups_were_observed_for_relapse._Mice_receiving_no_rIL-2_therapy_relapsed_and_died_within_50_days_after_BMT,_whereas_mice_receiving_rIL-2_showed_long-term_disease-free_survival._Optimal_time_for_administration_of_rIL-2_was_noted_at_3_weeks_post-BMT,_with_90%_of_the_mice_surviving_with_no_evidence_of_disease_for_more_than_1_year._Similarly,_when_10(4)_BCL1_cells_were_given_1_day_after_syngeneic_BMT_to_simulate_minimal_residual_disease_after_syngeneic_BMT,_rIL-2_therapy_administered_at_14_days_post-BMT_seemed_effective_in_prolonging_disease-free_survival_in_contrast_to_the_same_regimen_given_at_1_day_after_BMT._Our_data_suggest_that_immunotherapy_with_rIL-2_should_be_further_investigated_as_a_new_immunotherapeutic_tool_for_decreasing_the_relapse_rate_after_BMT_for_hematologic_malignancies.